Low frequency of skin cancers in vitiligo patients

Vitiligo is a disease characterized by discoloration of the skin and hair as a result of damage of melanocytes. The exact mechanism of the disease is still unknown. Theories about the pathogenesis focus on autoimmune, neurogenic and autocytotoxic mechanisms. There is a decreased risk of incidence of skin cancers in patients with vitiligo. The relation between vitiligo and decreased frequency of cases of malignant melanoma (MM) may be a consequence of the immune response to antigens, which are common for melanocytes and MM cells. Genetic studies indicate a mutually exclusive relationship of melanoma and vitiligo. This disease is also associated with a polymorphism in the TYR gene which encodes tyrosinase. Studies also indicate a decreased risk of incidence of nonmelanoma skin cancers (NMSC) in patients with vitiligo.

[1]  A. Zwinderman,et al.  Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Yosipovitch,et al.  Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature. , 2015, Acta dermato-venereologica.

[3]  D. Abeni,et al.  Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. , 2014, Journal of the American Academy of Dermatology.

[4]  R. Czajkowski,et al.  Current aspects of vitiligo genetics , 2014, Postepy dermatologii i alergologii.

[5]  Niamh A. O'Sullivan,et al.  Tanning bed and nail lamp use and the risk of cutaneous malignancy: A review of the literature , 2014, The Australasian journal of dermatology.

[6]  E. Torres-Lopez,et al.  Immunological Basis of Melanoma-Associated Vitiligo-Like Depigmentation , 2014 .

[7]  M. Bosseila,et al.  Broadband ultraviolet A vs. psoralen ultraviolet A in the treatment of vitiligo: a randomized controlled trial , 2013, Clinical and experimental dermatology.

[8]  L. Butterfield,et al.  Melanoma‐associated leukoderma – immunology in black and white? , 2013, Pigment cell & melanoma research.

[9]  D. Parsad,et al.  Stability in Vitiligo: Is there a Perfect Way to Predict it? , 2013, Journal of cutaneous and aesthetic surgery.

[10]  T. Nijsten,et al.  Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners , 2013, The British journal of dermatology.

[11]  J. Murase,et al.  A review of monochromatic excimer light in vitiligo , 2012, The British journal of dermatology.

[12]  L. Misery,et al.  Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  R. Stern.  The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. , 2012, Journal of the American Academy of Dermatology.

[14]  R. Sánchez-Porras,et al.  Immunopathogenesis of vitiligo. , 2011, Autoimmunity reviews.

[15]  Meaghan Daly,et al.  Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. , 2011, Journal of the American Academy of Dermatology.

[16]  A. Feily,et al.  Why vitiligo is associated with fewer risk of skin cancer? Providing a molecular mechanism , 2011, Archives of Dermatological Research.

[17]  R. Spritz.  Recent progress in the genetics of generalized vitiligo. , 2011, Journal of genetics and genomics = Yi chuan xue bao.

[18]  J. Nordlund.  VITILIGO: A REVIEW OF SOME FACTS LESSER KNOWN ABOUT DEPIGMENTATION , 2011, Indian journal of dermatology.

[19]  E. Dellambra,et al.  Vitiligo: pathogenetic hypotheses and targets for current therapies. , 2010, Current drug metabolism.

[20]  Jo Lambert,et al.  Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. , 2010, The New England journal of medicine.

[21]  P. Quaglino,et al.  Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Malvehy,et al.  Genome-wide association study identifies three loci associated with melanoma risk , 2009, Nature Genetics.

[23]  K. Yu,et al.  Metastatic malignant melanoma associated with vitiligo‐like depigmentation , 2009, Clinical and experimental dermatology.

[24]  M. Picardo,et al.  Clinical practice. Vitiligo. , 2009, The New England journal of medicine.

[25]  B. Thiers.  Narrow-Band UVB Induces More Carcinogenic Skin Tumors than Broad-Band UVB through the Formation of Cyclobutane Pyrimidine Dimer , 2009 .

[26]  M J Watts,et al.  Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.

[27]  I. Hamzavi,et al.  An update on new and emerging options for the treatment of vitiligo. , 2008, Skin therapy letter.

[28]  F. Chu,et al.  Inactivation of glutathione peroxidase activity contributes to UV-induced squamous cell carcinoma formation. , 2007, Cancer research.

[29]  Ö. Tulunay,et al.  Vitiligo associated with malignant melanoma and lupus erythematosus , 2007, The Journal of dermatology.

[30]  A. Shokoohi,et al.  The course of melanoma-associated vitiligo: report of a case. , 2006, Melanoma research.

[31]  D. Gawkrodger,et al.  Vitiligo presentation in adults , 2005, Clinical and experimental dermatology.

[32]  R. Stern,et al.  High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. , 2005, The Journal of investigative dermatology.

[33]  S. Moretti,et al.  New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. , 2002, Pigment cell research.

[34]  S. Steinberg,et al.  Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Tobin,et al.  Melanocytes are not absent in lesional skin of long duration vitiligo. , 2000, The Journal of pathology.

[36]  R. Stern.  Malignant melanoma in patients treated for psoriasis with PUVA , 1999, Photodermatology, photoimmunology & photomedicine.

[37]  S. Rodriguez-Cuevas,et al.  Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma. , 1998, Archives of medical research.

[38]  N. Taniguchi,et al.  Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. , 1992, Biochemical and biophysical research communications.